Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Chemoresistance in Glioma

  • Chapter
  • First Online:
New Advances on Disease Biomarkers and Molecular Targets in Biomedicine

Abstract

Glioma remains one of the most aggressive and lethal form of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor with a median overall survival of just over 1 year. Most patients would die of tumour recurrences because of their tumours’ intrinsic or acquired resistance against chemotherapy. Researchers have strived to better understand the molecular mechanisms of chemoresistance in glioma by using different experimental models, and to direct targeted therapeutics in an attempt to overcome treatment resistance. Currently, different pathways that can confer drug resistance have been identified including DNA damage repair, drug efflux, hypoxia, cancer stem cells, and microRNAs (miRNAs). This chapter will discuss how modulation of these signalling pathways may potentially lead to the development of novel approaches for the treatment of this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Walker C, Baborie A, Crooks D, Wilkins S, Jenkinson MD (2011) Biology, genetics and imaging of glial cell tumours. Br J Radiol 84(2):S90–S106

    Article  PubMed  Google Scholar 

  2. Ostrom QT, McCulloh C, Chen Y, Devine K, Wolinsky Y, Davitkov P, Robbins S, Cherukuri R, Patel A, Gupta R, Cohen M, Barrios JV, Brewer C, Schilero C, Smolenski K, McGraw M, Denk B, Naska T, Laube F, Steele R, Greene D, Kastl A, Bell S, Aziz D, Chiocca EA, McPherson C, Warnick R, Barnett GH, Sloan AE, Barnholtz-Sloan JS (2012) Family history of cancer in benign brain tumor subtypes versus gliomas. Front Oncol 2:19

    Article  PubMed  Google Scholar 

  3. Kesari S (2011) Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol 38(Suppl 4):S2–S10

    Article  PubMed  Google Scholar 

  4. Jiang J, Sun X, Wang W, Jin X, Bo X, Li Z, Bian A, Jiu J, Wang X, Liu D, Hui X, Wang Y, Wang A, Ding L (2012) Tumor microRNA-335 expression is associated with poor prognosis in human glioma. Med Oncol 29(5):3472–3477

    Article  PubMed  CAS  Google Scholar 

  5. Zhang X, Yang H, Gong B, Jiang C, Yang L (2012) Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis. J Neurooncol 107:281–288

    Article  PubMed  CAS  Google Scholar 

  6. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14:2900–2908

    Article  PubMed  CAS  Google Scholar 

  7. Zhang J, Stevens MF, Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102–114

    PubMed  CAS  Google Scholar 

  8. Sun S, Wong TS, Zhang XQ, Pu JK, Lee NP, Day PJ, Ng GK, Lui WM, Leung GK (2012) Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol 107:89–100

    Article  PubMed  CAS  Google Scholar 

  9. Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2:552–560

    Article  PubMed  CAS  Google Scholar 

  10. Tisdale MJ (1987) Antitumor imidazotetrazines–XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 36:457–462

    Article  PubMed  CAS  Google Scholar 

  11. Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198–206

    Article  PubMed  CAS  Google Scholar 

  12. Mehta K, Siddik ZH (2009) Drug resistance in cancer cells. Springer, New York, NY

    Google Scholar 

  13. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296–307

    Article  PubMed  CAS  Google Scholar 

  14. Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS (1999) O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5:807–814

    PubMed  CAS  Google Scholar 

  15. Hotta T, Saito Y, Fujita H, Mikami T, Kurisu K, Kiya K, Uozumi T, Isowa G, Ishizaki K, Ikenaga M (1994) O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 21:135–140

    Article  PubMed  CAS  Google Scholar 

  16. Bacolod MD, Johnson SP, Pegg AE, Dolan ME, Moschel RC, Bullock NS, Fang Q, Colvin OM, Modrich P, Bigner DD, Friedman HS (2004) Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 3:1127–1135

    PubMed  CAS  Google Scholar 

  17. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612–5619

    PubMed  CAS  Google Scholar 

  18. Esteller M, Herman JG (2004) Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23:1–8

    Article  PubMed  CAS  Google Scholar 

  19. Sabharwal A, Middleton MR (2006) Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 6:355–363

    Article  PubMed  CAS  Google Scholar 

  20. Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, Lapierre F, Larsen CJ, Karayan-Tapon L (2004) Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68:275–283

    Article  PubMed  CAS  Google Scholar 

  21. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871–1874

    Article  PubMed  CAS  Google Scholar 

  22. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199

    Article  PubMed  CAS  Google Scholar 

  23. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354

    Article  PubMed  CAS  Google Scholar 

  24. Jung TY, Jung S, Moon KS, Kim IY, Kang SS, Kim YH, Park CS, Lee KH (2010) Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 23:1269–1276

    Article  PubMed  CAS  Google Scholar 

  25. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87:71–78

    Article  PubMed  CAS  Google Scholar 

  26. von Bueren AO, Bacolod MD, Hagel C, Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer MA, Friedman HS, Marra G, Kool M, Rutkowski S (2012) Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. Br J Cancer 107:1399–1408

    Article  CAS  Google Scholar 

  27. Branch P, Aquilina G, Bignami M, Karran P (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362:652–654

    Article  PubMed  CAS  Google Scholar 

  28. Kondo N, Takahashi A, Ono K, Ohnishi T (2010) DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids 2010:543531

    Google Scholar 

  29. Margison GP, Santibanez-Koref MF (2002) O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 24:255–266

    Article  PubMed  CAS  Google Scholar 

  30. Rellecke P, Kuchelmeister K, Schachenmayr W, Schlegel J (2004) Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas. J Neurosurg 101:653–658

    Article  PubMed  CAS  Google Scholar 

  31. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O’Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66:3987–3991

    Article  PubMed  CAS  Google Scholar 

  32. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15:4622–4629

    Article  PubMed  CAS  Google Scholar 

  33. Karran P (2001) Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22:1931–1937

    Article  PubMed  CAS  Google Scholar 

  34. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL (2000) Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 46:507–516

    Article  PubMed  CAS  Google Scholar 

  35. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038–2045

    Article  PubMed  CAS  Google Scholar 

  36. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loffler M, Weller M, Reifenberger G, Tonn JC (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659–670

    Article  PubMed  CAS  Google Scholar 

  37. Yoshimoto K, Mizoguchi M, Hata N, Murata H, Hatae R, Amano T, Nakamizo A, Sasaki T (2012) Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol 2:186

    Article  PubMed  CAS  Google Scholar 

  38. Lindahl T, Karran P, Wood RD (1997) DNA excision repair pathways. Curr Opin Genet Dev 7:158–169

    Article  PubMed  CAS  Google Scholar 

  39. Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN, Tang JB, Sobol RW (2011) Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res 71:2308–2317

    Article  PubMed  CAS  Google Scholar 

  40. Aguilar-Quesada R, Munoz-Gamez JA, Martin-Oliva D, Peralta-Leal A, Quiles-Perez R, Rodriguez-Vargas JM, Ruiz de Almodovar M, Conde C, Ruiz-Extremera A, Oliver FJ (2007) Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation. Curr Med Chem 14:1179–1187

    Article  PubMed  CAS  Google Scholar 

  41. Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP (2002) Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 100:615–617

    Article  PubMed  CAS  Google Scholar 

  42. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12:1577–1584

    Article  PubMed  CAS  Google Scholar 

  43. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25:2540–2545

    Article  PubMed  CAS  Google Scholar 

  44. Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR (2010) Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res 16:743–749

    Article  PubMed  CAS  Google Scholar 

  45. Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME (2002) O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther 1:943–948

    PubMed  CAS  Google Scholar 

  46. Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM (2005) Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 23:7646–7653

    Article  PubMed  CAS  Google Scholar 

  47. Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, Webber SE, Eastman BW, Almassy R, Li J, Curtin NJ, Newell DR, Calvert AH, Griffin RJ, Golding BT (2003) Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 46:210–213

    Article  PubMed  CAS  Google Scholar 

  48. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917–7923

    Article  PubMed  CAS  Google Scholar 

  49. Drew Y, Plummer R (2009) PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 12:153–156

    Article  PubMed  CAS  Google Scholar 

  50. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134

    Article  PubMed  CAS  Google Scholar 

  51. Montaldi AP, Sakamoto-Hojo ET (2012) Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. 2012 Jul 25. Epub ahead of print

    Google Scholar 

  52. Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92:317–335

    Article  PubMed  CAS  Google Scholar 

  53. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M (2005) Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9:617–628

    Article  PubMed  CAS  Google Scholar 

  54. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322–1326

    Article  PubMed  CAS  Google Scholar 

  55. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, Borea PA (2007) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 72:162–172

    Article  PubMed  CAS  Google Scholar 

  56. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28:3949–3959

    Article  PubMed  CAS  Google Scholar 

  57. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N, Kristensen BW (2011) Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103:43–58

    Article  PubMed  CAS  Google Scholar 

  58. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S (2002) Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 99:7021–7026

    Article  PubMed  CAS  Google Scholar 

  59. Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, Leonetti C, Safran M, Rechavi G, Givol D, Farsetti A, D’Orazi G (2010) Zinc downregulates HIF-1alpha and inhibits its activity in tumor cells in vitro and in vivo. PLoS One 5:e15048

    Article  PubMed  CAS  Google Scholar 

  60. Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D (2010) HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer 10:605

    Article  PubMed  CAS  Google Scholar 

  61. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8:1867–1877

    Article  PubMed  CAS  Google Scholar 

  62. Lu H, Li Y, Shu M, Tang J, Huang Y, Zhou Y, Liang Y, Yan G (2009) Hypoxia-inducible factor-1alpha blocks differentiation of malignant gliomas. FEBS J 276:7291–7304

    Article  PubMed  CAS  Google Scholar 

  63. Dai S, Huang ML, Hsu CY, Chao KS (2003) Inhibition of hypoxia inducible factor 1alpha causes oxygen-independent cytotoxicity and induces p53 independent apoptosis in glioblastoma cells. Int J Radiat Oncol Biol Phys 55:1027–1036

    Article  PubMed  CAS  Google Scholar 

  64. Sapra P, Kraft P, Pastorino F, Ribatti D, Dumble M, Mehlig M, Wang M, Ponzoni M, Greenberger LM, Horak ID (2011) Potent and sustained inhibition of HIF-1alpha and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14:245–253

    Article  PubMed  CAS  Google Scholar 

  65. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, Zhong H (2001) ‘The metabolism of tumours’: 70 years later. Novartis Found Symp 240:251–260; discussion 260–254

    Google Scholar 

  66. Moen I, Tronstad KJ, Kolmannskog O, Salvesen GS, Reed RK, Stuhr LE (2009) Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. BMC Cancer 9:446

    Article  PubMed  CAS  Google Scholar 

  67. Sun S, Lee D, Lee NP, Pu JK, Wong ST, Lui WM, Fung CF, Leung GK (2012) Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J Neurooncol 109:467–475

    Article  PubMed  CAS  Google Scholar 

  68. Challen GA, Little MH (2006) A side order of stem cells: the SP phenotype. Stem Cells 24:3–12

    Article  PubMed  Google Scholar 

  69. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284

    Article  PubMed  CAS  Google Scholar 

  70. Gage FH (2000) Mammalian neural stem cells. Science 287:1433–1438

    Article  PubMed  CAS  Google Scholar 

  71. Temple S (2001) The development of neural stem cells. Nature 414:112–117

    Article  PubMed  CAS  Google Scholar 

  72. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178–15183

    Article  PubMed  CAS  Google Scholar 

  73. Persano L, Rampazzo E, Basso G, Viola G (2013) Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol 85(5):612–622

    Article  PubMed  CAS  Google Scholar 

  74. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021

    Article  PubMed  CAS  Google Scholar 

  75. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165–172

    Article  PubMed  CAS  Google Scholar 

  76. Chua C, Zaiden N, Chong KH, See SJ, Wong MC, Ang BT, Tang C (2008) Characterization of a side population of astrocytoma cells in response to temozolomide. J Neurosurg 109:856–866

    Article  PubMed  CAS  Google Scholar 

  77. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238–1241

    Article  PubMed  CAS  Google Scholar 

  78. Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P, Konda B, Wachsmann-Hogiu S, Black KL, Yu JS (2007) Spheres isolated from 9 L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645–1653

    Article  PubMed  CAS  Google Scholar 

  79. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706–5715

    Article  PubMed  CAS  Google Scholar 

  80. Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, Weiss S, Cairncross JG (2010) Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 12:756–760

    Article  PubMed  CAS  Google Scholar 

  81. Dirks PB (2008) Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci 363:139–152

    Article  PubMed  CAS  Google Scholar 

  82. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X (2008) Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One 3:e1936

    Article  PubMed  CAS  Google Scholar 

  83. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14:8205–8212

    Article  PubMed  CAS  Google Scholar 

  84. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123–129

    Article  PubMed  CAS  Google Scholar 

  85. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67

    Article  PubMed  CAS  Google Scholar 

  86. Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells—much more complex than expected. Mol Cancer 10:128

    Article  PubMed  CAS  Google Scholar 

  87. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897–2909

    Article  PubMed  CAS  Google Scholar 

  88. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH (2008) Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88:808–815

    Article  PubMed  CAS  Google Scholar 

  89. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6:421–432

    Article  PubMed  CAS  Google Scholar 

  90. Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, Febbo PG, Wechsler-Reya RJ (2009) Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 15:135–147

    Article  PubMed  CAS  Google Scholar 

  91. Yamada R, Nakano I (2012) Glioma stem cells: their role in chemoresistance. World Neurosurg 77:237–240

    Article  PubMed  Google Scholar 

  92. Kondo T (2006) Brain cancer stem-like cells. Eur J Cancer 42:1237–1242

    Article  PubMed  CAS  Google Scholar 

  93. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

    Article  PubMed  CAS  Google Scholar 

  94. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233

    Article  PubMed  CAS  Google Scholar 

  95. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111

    Article  PubMed  CAS  Google Scholar 

  96. Delva L, Zelent A, Naoe T, Fenaux P, Waxman S, Degos L, Chomienne C (2007) Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology. Cancer Res 67:10635–10637

    Google Scholar 

  97. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761–765

    Article  PubMed  CAS  Google Scholar 

  98. Tunici P, Irvin D, Liu G, Yuan X, Zhaohui Z, Ng H, Yu JS (2006) Brain tumor stem cells: new targets for clinical treatments? Neurosurg Focus 20:E27

    Article  PubMed  Google Scholar 

  99. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK (2012) Antitumor activity of NVP-BKM120—a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18:184–195

    Article  PubMed  CAS  Google Scholar 

  100. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK (2010) Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 12:559–569

    Article  PubMed  CAS  Google Scholar 

  101. Gallia GL, Tyler BM, Hann CL, Siu IM, Giranda VL, Vescovi AL, Brem H, Riggins GJ (2009) Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther 8:386–393

    Article  PubMed  CAS  Google Scholar 

  102. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA (2011) Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 13:384–392

    Article  PubMed  CAS  Google Scholar 

  103. Lu C, Shervington A (2008) Chemoresistance in gliomas. Mol Cell Biochem 312:71–80

    Article  PubMed  CAS  Google Scholar 

  104. Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35:161–204

    Article  PubMed  CAS  Google Scholar 

  105. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N (2003) Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94:15–21

    Article  PubMed  CAS  Google Scholar 

  106. Ling V (1995) P-glycoprotein: its role in drug resistance. Am J Med 99:31S–34S

    Article  PubMed  CAS  Google Scholar 

  107. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Shen DW, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538–4542

    Article  PubMed  CAS  Google Scholar 

  108. Bohacova V, Sulova Z, Dovinova I, Polakova E, Barancik M, Uhrik B, Orlicky J, Breier A (2006) L1210 cells cultivated under the selection pressure of doxorubicin or vincristine express common mechanisms of multidrug resistance based on the overexpression of P-glycoprotein. Toxicol In Vitro 20:1560–1568

    Article  PubMed  CAS  Google Scholar 

  109. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147–155

    Article  PubMed  CAS  Google Scholar 

  110. Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M, Berger W (2002) Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 57:27–36

    Article  PubMed  Google Scholar 

  111. Korshunov A, Sycheva R, Timirgaz V, Golanov A (1999) Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases. J Neurooncol 45:219–227

    Article  PubMed  CAS  Google Scholar 

  112. Andersson U, Malmer B, Bergenheim AT, Brannstrom T, Henriksson R (2004) Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 23:21–27

    PubMed  CAS  Google Scholar 

  113. Regina A, Demeule M, Laplante A, Jodoin J, Dagenais C, Berthelet F, Moghrabi A, Beliveau R (2001) Multidrug resistance in brain tumors: roles of the blood–brain barrier. Cancer Metastasis Rev 20:13–25

    Article  PubMed  CAS  Google Scholar 

  114. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF (2013) Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41:33–39

    Article  PubMed  CAS  Google Scholar 

  115. Deeley RG, Cole SP (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580:1103–1111

    Article  PubMed  CAS  Google Scholar 

  116. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D (1994) ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54:4833–4836

    PubMed  CAS  Google Scholar 

  117. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M (1999) Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 14:123–131

    PubMed  CAS  Google Scholar 

  118. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55:929–937

    PubMed  CAS  Google Scholar 

  119. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121

    Article  PubMed  CAS  Google Scholar 

  120. Quezada C, Peignan L, Segura R, Riquelme F, Melo R, Rojas ZD, Ayach F, San Martin R, Carcamo JG (2011) Study of resistance to chemotherapy mediated by ABC transporters in biopsies of glioblastoma multiforme. Rev Med Chil 139:415–424

    Article  PubMed  CAS  Google Scholar 

  121. Haga S, Hinoshita E, Ikezaki K, Fukui M, Scheffer GL, Uchiumi T, Kuwano M (2001) Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 92:211–219

    Article  PubMed  CAS  Google Scholar 

  122. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337–5339

    PubMed  CAS  Google Scholar 

  123. Doyle L, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358

    Article  PubMed  CAS  Google Scholar 

  124. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman T (2001) The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33:503–511

    Article  PubMed  CAS  Google Scholar 

  125. Ginguene C, Champier J, Maallem S, Strazielle N, Jouvet A, Fevre-Montange M, Ghersi-Egea JF (2010) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol 20:926–935

    PubMed  CAS  Google Scholar 

  126. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, Walsh K (2003) Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 278:39068–39075

    Article  PubMed  CAS  Google Scholar 

  127. Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y (2012) The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. Oncol Rep 27:1703–1709

    PubMed  CAS  Google Scholar 

  128. Li WQ, Li YM, Tao BB, Lu YC, Hu GH, Liu HM, He J, Xu Y, Yu HY (2010) Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 16:HY27–HY30

    PubMed  Google Scholar 

  129. Jin Y, Bin ZQ, Qiang H, Liang C, Hua C, Jun D, Dong WA, Qing L (2009) ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol 135:1369–1376

    Article  PubMed  CAS  Google Scholar 

  130. Park K (2012) The role of major vault protein (MVP) in drug resistance. J Control Release 163:266

    Article  PubMed  CAS  Google Scholar 

  131. Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Cross JH, Scheper RJ, Harding BN, Thom M (2003) Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44:1388–1396

    Article  PubMed  CAS  Google Scholar 

  132. Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M (2001) Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 94:377–382

    Article  PubMed  CAS  Google Scholar 

  133. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ (1996) Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 19:191–197

    Article  PubMed  CAS  Google Scholar 

  134. Siva AC, Raval-Fernandes S, Stephen AG, LaFemina MJ, Scheper RJ, Kickhoefer VA, Rome LH (2001) Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 92:195–202

    Article  PubMed  CAS  Google Scholar 

  135. Han M, Lv Q, Tang XJ, Hu YL, Xu DH, Li FZ, Liang WQ, Gao JQ (2012) Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. J Control Release 163:136–144

    Article  PubMed  CAS  Google Scholar 

  136. Yang J, Nagasawa DT, Spasic M, Amolis M, Choy W, Garcia HM, Prins RM, Liau LM, Yang I (2012) Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies. Neurosurg Clin N Am 23:451–458

    Article  PubMed  Google Scholar 

  137. Hubensack M, Muller C, Hocherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A (2008) Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134:597–607

    Article  PubMed  CAS  Google Scholar 

  138. Bahr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W (2003) P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol 13:482–494

    Article  PubMed  Google Scholar 

  139. Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM (2002) Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98:173–180

    Article  PubMed  CAS  Google Scholar 

  140. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE (2009) Cell death. N Engl J Med 361:1570–1583

    Article  PubMed  CAS  Google Scholar 

  141. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y (1994) Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54:6–8

    PubMed  CAS  Google Scholar 

  142. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S (1997) BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 90:1168–1174

    PubMed  CAS  Google Scholar 

  143. Doucette T, Yang Y, Zhang W, Fuller GN, Suki D, Fults DW, Rao G (2011) Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. Int J Cancer 129:2093–2103

    Article  PubMed  CAS  Google Scholar 

  144. McDonald FE, Ironside JW, Gregor A, Wyatt B, Stewart M, Rye R, Adams J, Potts HW (2002) The prognostic influence of bcl-2 in malignant glioma. Br J Cancer 86:1899–1904

    Article  PubMed  CAS  Google Scholar 

  145. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC (1997) Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150:805–814

    PubMed  CAS  Google Scholar 

  146. Kouri FM, Jensen SA, Stegh AH (2012) The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. ScientificWorldJournal 2012:838916

    Article  PubMed  CAS  Google Scholar 

  147. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M, Meyermann R (1999) BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67:763–768

    Article  PubMed  CAS  Google Scholar 

  148. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633–2643

    Article  PubMed  CAS  Google Scholar 

  149. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, DePinho RA, Chin L (2007) Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 21:98–111

    Article  PubMed  CAS  Google Scholar 

  150. George J, Banik NL, Ray SK (2009) Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res 34:66–78

    Article  PubMed  CAS  Google Scholar 

  151. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH (2011) Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 16:59–70

    Article  PubMed  CAS  Google Scholar 

  152. Stegh AH, Kesari S, Mahoney JE, Jenq HT, Forloney KL, Protopopov A, Louis DN, Chin L, DePinho RA (2008) Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci USA 105:10703–10708

    Article  PubMed  CAS  Google Scholar 

  153. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748–754

    Article  PubMed  CAS  Google Scholar 

  154. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M (2007) Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10:81–100

    Article  PubMed  CAS  Google Scholar 

  155. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079–5086

    PubMed  CAS  Google Scholar 

  156. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962–6970

    PubMed  CAS  Google Scholar 

  157. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N, Kiessling M (1994) Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56:72–77

    Article  PubMed  CAS  Google Scholar 

  158. Jiang Z, Zheng X, Rich KM (2003) Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 84:273–281

    Article  PubMed  CAS  Google Scholar 

  159. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS (2011) Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov 1:524–538

    Article  PubMed  CAS  Google Scholar 

  160. Patel M, Vogelbaum MA, Barnett GH, Jalali R, Ahluwalia MS (2012) Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs 21:1247–1266

    Article  PubMed  CAS  Google Scholar 

  161. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838–4848

    PubMed  CAS  Google Scholar 

  162. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268–1274

    Article  PubMed  CAS  Google Scholar 

  163. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12:95–103

    Article  PubMed  CAS  Google Scholar 

  164. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    Article  PubMed  CAS  Google Scholar 

  165. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL, Kuo JS (2012) Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia 14:420–428

    PubMed  CAS  Google Scholar 

  166. Neyns B, Sadones J, Joosens E, Bouttens F, Verbeke L, Baurain JF, D’Hondt L, Strauven T, Chaskis C, In’t Veld P, Michotte A, De Greve J (2009) Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 20:1596–1603

    Article  PubMed  CAS  Google Scholar 

  167. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sorensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS (2010) Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 12:508–516

    PubMed  CAS  Google Scholar 

  168. Fernandez LA, Northcott PA, Taylor MD, Kenney AM (2009) Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle 8:4049–4054

    Article  Google Scholar 

  169. Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334:1351–1358

    Article  PubMed  CAS  Google Scholar 

  170. Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, Smrcka M, Svoboda M, Dolezalova H, Novakova J, Valik D, Vyzula R, Michalek J (2010) MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 57:264–269

    Article  PubMed  CAS  Google Scholar 

  171. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65:6029–6033

    Article  PubMed  CAS  Google Scholar 

  172. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28:5369–5380

    Article  PubMed  CAS  Google Scholar 

  173. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352:255–264

    Article  PubMed  CAS  Google Scholar 

  174. Wong ST, Zhang XQ, Zhuang JT, Chan HL, Li CH, Leung GK (2012) MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res 32:2835–2841

    PubMed  CAS  Google Scholar 

  175. Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z, Zhang J, Wang Y, Yan W, Fu Z, You Y (2012) MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol 40:119–129

    PubMed  Google Scholar 

  176. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I, Yamashita S (2010) miR-195, miR-455-3p and miR-10a are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296:241–248

    Article  PubMed  CAS  Google Scholar 

  177. Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, Araki Y, Kuga D, Nakamizo A, Amano T, Ma X, Hayashi K, Sasaki T (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 16:4289–4297

    Article  PubMed  CAS  Google Scholar 

  178. Neelakandan K, Babu P, Nair S (2012) Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr Cancer Drug Targets 12:716–740

    Article  PubMed  CAS  Google Scholar 

  179. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM (2011) Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520 h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol 81:783–792

    Article  PubMed  CAS  Google Scholar 

  180. Zhou X, Zhang J, Jia Q, Ren Y, Wang Y, Shi L, Liu N, Wang G, Pu P, You Y, Kang C (2010) Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3. Oncol Rep 24:195–201

    Article  PubMed  CAS  Google Scholar 

  181. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76:582–588

    Article  PubMed  CAS  Google Scholar 

  182. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I (2012) MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 22:198–205

    Article  PubMed  CAS  Google Scholar 

  183. Li Y, Zhao S, Zhen Y, Li Q, Teng L, Asai A, Kawamoto K (2011) A miR-21 inhibitor enhances apoptosis and reduces G(2)-M accumulation induced by ionizing radiation in human glioblastoma U251 cells. Brain Tumor Pathol 28:209–214

    Article  PubMed  CAS  Google Scholar 

  184. Bader AG, Brown D, Stoudemire J, Lammers P (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18:1121–1126

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China

    Stella Sun, Derek Lee & Gilberto K. K. Leung

Authors
  1. Stella Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derek Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilberto K. K. Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gilberto K. K. Leung .

Editor information

Editors and Affiliations

  1. Faculty of Medicine Building, Department of Surgery, University of Hong Kong, Sassoon Road 21, Hong Kong, Hong Kong SAR

    Nikki P. Lee

  2. Center for Biomedical Research, Population Council, York Ave. 1230, NEW YORK, 10021, New York, USA

    C.Y. Cheng

  3. Yong Loo Lin School of Medicine, Department of Pharmacology and Departmen, National University of Singapore, Medical Drive 10, Singapore, 117597, Singapore

    John M. Luk

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sun, S., Lee, D., Leung, G.K.K. (2013). Chemoresistance in Glioma. In: Lee, N., Cheng, C., Luk, J. (eds) New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-456-2_14

Download citation

Publish with us

Policies and ethics

Search

Navigation